Cepheid lowered guidance could lead to upside potential, says Cowen Cowen expects Cepheid to be under pressure today following the company's lowered guidance. The firm believes the guidance could position to the company to generated potential upside citing the establishment of confidence in execution, modest multiple expansion, and potential for upside to guidance. Shares are Outperform rated.
Cepheid receives FDA emergency use authorization for Xpert Ebola diagnostic test Cepheid announced it has received Emergency Use Authorization from the FDA for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours. The test runs on the Cepheid GeneXpert Systems. Xpert Ebola has been authorized by FDA under an Emergency Use Authorization for use by CLIA moderate and high complexity laboratories or similarly qualified non-U.S. laboratories. The test will begin shipping in April. Cepheid's Xpert Ebola has not been FDA cleared or approved, but will remain available in the U.S. as an EUA product as long as the declared emergency remains in effect or it ceases to be authorized by FDA.